Silicon Valley Healthcare Investment Annual Report: $1.55 Billion Spent to Launch 35 IPO Companies

▲ Niche investors show strong interest in neuroscience In fact, neuro-related healthcare startups emerged as a dark horse trend in 2017, attracting attention from niche investors and incubators. Moreover, the broader AI wave has further fueled investor—especially newly entering tech investors—interest in computational diagnostic tools, driving investment to record highs. ▲ Investors favor smaller Series A rounds for diagnostic tools Funding for medical diagnostic tools (dx/tools) rose by 40% in 2017, reaching $2.8 billion globally (China participated in one of the top five global deals, amounting to $30 million). R&D tools and diagnostic tests were particularly hot areas. Diagnostic analytics (Dx Analytics), however, saw weaker Series A activity due to greater clinical validation requirements—though later-stage funding or investor allocation increased. ▲ Illustration of investors focusing on diagnostic tools ▲ Investors prioritize R&D tools and diagnostic tests Although innovative medical diagnostic tools attracted significant interest—and Series A deal counts rose—the absence of clear regulatory pathways and reimbursement mechanisms led to a decline in total Series A funding volume. In other words, investors are making smaller individual bets. Nevertheless, multimillion-dollar Series A deals and AI-focused healthcare investments both clustered within the diagnostic tools category. ▲ Liquid biopsy for oncology surged in 2017 Investment in liquid biopsy soared, with three companies—Guardant Health (founded in 2013 in California, launched its Guardant360 liquid cancer screening test in 2014), GRAIL (founded in 2016 in Silicon Valley, focused on blood-based genomic testing and developing pan-cancer screening technology), and Human Longevity (founded in 2013 in California, specializing in genomic research)—together raising $1.8 billion. Exit activity: Focus on early-stage biopharma and medtech companies ▲ Biopharma exits backed by venture capital (2013–2017) Biopharma witnessed an IPO surge, with 19 IPOs occurring in Q4 alone—31 total for the year, surpassing the full-year 2016 total. However, this also signaled a slowdown in large-scale M&A exits (14 deals). ▲ Biopharma companies’ IP…

Global Pharma News — October 23, 2025

4. Novartis sues AstraZeneca’s Alexion over alleged false marketing of Ultomiris Novartis has filed a lawsuit against Alexion, AstraZeneca’s rare-disease unit, alleging that certain marketing materials for Ultomiris created inaccurate impressions about Novartis’ competing drug Fabhalta, constituting false and misleading promotion. 5. Flagship launches AI-driven drug discovery company Expedition, secures Pfizer collaboration Venture giant Flagship Pioneering invested $50 million to launch Expedition Medicines, an AI-powered generative chemistry drug discovery company. Expedition has already established a collaboration with Pfizer, focusing on oncology and immunology. 6. Alector cuts nearly half its workforce after GSK antibody partnership fails Alector Therapeutics announced a 49% workforce reduction following the Phase 3 clinical trial failure of latozinemab—a monoclonal antibody developed in partnership with GlaxoSmithKline—for frontotemporal dementia. Dr. Sara Kenkare-Mitra, President and Head of R&D, resigned. 7. Trump administration prepares Section 301 investigation into foreign drug pricing According to the Financial Times, the White House is preparing to investigate whether U.S. trade partners underpay for pharmaceuticals. The probe will be conducted under Section 301 of the Trade Act of 1974 and could trigger new tariff threats. 8. Sanofi’s $1.7B rare-disease bet efdoralprin alfa outperforms CSL’s Zemaira in Phase 2 Sanofi’s $1.7 billion rare-disease acquisition candidate, efdoralprin alfa, outperformed standard therapy Zemaira (CSL) on both primary and key secondary endpoints in a Phase 2 clinical trial—laying the groundwork for discussions with regulators on next steps. 9. Arcturus’ inhaled mRNA therapy fails to show efficacy in cystic fibrosis trial; stock plunges nearly 50% Arcturus Therapeutics reported that its investigational inhaled mRNA therapy demonstrated no clinical efficacy in a mid-stage cystic fibrosis trial, despite favorable safety data—causing its stock price to drop nearly 50%.

Electra Therapeutics Targets $977.6 Million Valuation in US IPO

Sep 14, 2026

Electra Therapeutics targets a $977.6 million valuation in its U.S. IPO to fund clinical trials for its lead drug ipsoprubart and candidate ELA822 targeting immunological diseases and cancer. The company plans to raise up to $346.7 million via a Nasdaq listing.

reuters

2026-09-14

Electra Therapeutics Targets $977.6 Million Valuation in US IPO

Electra Therapeutics Targets $977.6 Million Valuation in US IPO

FAQ